Searching for Answers: NCBI’s David Lipman



Juan Carlos Perez (IDG News Service) recently spoke with David Lipman, director of the National Center for Biotechnology Information, part of the National Library of Medicine, which hosts various life sciences databases, including the PubMed scientific literature database. Lipman discusses the emergence of Google and Yahoo as scientific research tools, as well as major improvements on tap to PubMed’s search functionality.

Some people view Google, etc., as increasingly useful research tools in the life sciences, joining PubMed and other established services. What is your opinion?

Lipman: People sometimes have this a bit backwards. The primary point is that there is a huge amount of information on the Web. The best way to make the Web more useful for research and education is to get more information out there. What we find on our site is that the more good-quality content that we add to a resource, the more it is being used. If you have more gene sequencing data, you have more searching. If you have more full text in PubMed Central, you have more searching.

While I want to give MSN and Yahoo and Google a lot of credit for doing a good job, the reality is that if there wasn’t content there, it wouldn’t matter how good those search engines were. And if the search engines were a little less good than they were, you would still be getting to a lot of good content... And if those search engines got better, it wouldn’t make as much of a difference as if there was more good peer-reviewed medical content. That would make a bigger impact.

What do you think about Google Scholar?

There is a lot of involvement of the library community in PubMed so it’s more transparent in terms of what could be there and isn’t there… So when you don’t find something, it might mean something because [PubMed] is updated [often] and its scope is well defined. When you search Google, Yahoo, or Google Scholar, it’s more open-ended what could be in there, and it’s not clear – when something isn’t there – why it’s not there. These things aren’t good or bad per se. It just means that there are advantages [in both types of services.] I’m thrilled when I see Google make the effort to do something with Google Scholar because I know it’s going to mean more people will make more discoveries. A lot of times they’re sending people to us as well, and that’s great.

Are you planning usability enhancements to PubMed?

We do a lot of things in PubMed to make it so you don’t have to know much and you can do a query and we’ll do a lot of interpretation of what you’re doing to try to make it simple. Although the interface doesn’t look that simple, if you just type in some stuff, we’re doing a lot of backend work to map things to other terms to make it easier. The problem we face with PubMed and our whole system is that to gain more of the advantages, you need to know more things. You need to poke around more.

We’re definitely looking at our user patterns more carefully now. You’ll see over the next year some significant changes in it, not so much to make it easier to use but to make it easier to make more discoveries with it. If you type something in, you’ll see more suggested additional links to look at … We can connect you up to related information much more effectively than we’ve been doing. We’ll make it easier to use in very powerful ways. I want more people to make more discoveries.

Are you talking about identifying search patterns from users so you can surface links they might be interested in?

If you did a search on, say, Alzheimer's disease, and you find a PubMed record that looks interesting to you … right now you go to that page and we may have done an incredible amount of work to link that up to all kinds of things – to information about genes that might be involved, to genetic versions of it, to related articles. And the reality is you have to poke around to see that – it’s sort of hidden in a way.

What we’ll do instead is, using computational tools, poke around for you and then put them right on the record. A lot of this is based on a much more careful analysis of how people are really using the site and what they’re really doing, and [questioning] why they aren’t doing some things more than they are. It’s about making the computer do a little more work so that the user just sees it. It’s just there and they don’t even have to think about it.

The bottom line for us is discovery. We want people to make discoveries, and if we’re using up real estate on the Web page for things people don’t click on, and if we can put things on there that would have been associated information, then we should do that.

Is there a specific initiative tied to these improvements?

Yes. I call it the Discovery Initiative. It’s something new. It’s been percolating. Last summer, I went out to visit Google and Amazon’s A9 [search engine] and the folks from Microsoft’s MSN came to visit. I also went up to Boston to meet with folks from the major hospitals there and MIT and Harvard. We’ve really been giving this a lot of thought. In many ways, we have had great success. Lots of people use the site and 2.25 terabytes of data are downloaded from our site everyday. And yet I find it very frustrating because we’ve connected up the scientific information in very precise and powerful ways: a protein structure to the chemical it’s bound to, to genetic data, you name it. All that is connected up. And yet very few of our users do more than very simple things with our site. It’s as if [they say], “That’s enough, I found the answer I’m looking for and I’m done.”

We want them to find answers to questions they didn’t even know they had. They can do that. People who are really experts at using this site can make discoveries almost on demand. … So this is a new initiative. We’ve always been working on making incremental improvements, but now I’m talking about something that is a more powerful shift. I’m hoping that without the users having to think about having to learn anything different, they’ll be able to take advantage of databases they didn’t know about and [make] connections between things they don’t have to ask for anymore. This is a new phase.

What stage is the initiative in right now?

We’ve been re-engineering our backend to make it more flexible on the front end and user interfaces and that’s moving along. We’re almost ready to roll that out. That wouldn’t necessarily be seen as a difference, initially, by users, but it does give us more flexibility in terms of the front-end stuff. A number of these issues we had [identified] as things we wanted to work towards over a year ago. Some of this is still in the discussion phase, some is very far along in terms of implementing, and some inevitably is going to be an experimental aspect. I’m hoping within a few months some of the initial beta aspects of it will be out there.

You said most changes will be implemented this year, but is this a multi-year effort?

It marks a change in perspective and philosophy that will lead to constant changes in the system [in coming years].

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .